Search
Search Results
##search.searchResults.foundPlural##
-
Should every patient with MDS get iron chelation – probably yes.
2430PDF: 1016HTML: 403 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
3259PDF: 954HTML: 6625Untitled: 291Untitled: 247Untitled: 265Untitled: 274 -
-
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1580PDF: 861HTML: 376 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1272PDF: 819HTML: 1543Figure 1: 261Figure 2: 266 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2715PDF: 877HTML: 5393 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3868PDF: 975HTML: 6889 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
2017PDF: 1242HTML: 350 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
2276PDF: 901HTML: 270 -
SIMPLE PERIPHERAL BLOOD SMEAR FINDINGS OF COVID-19 PATIENTS PROVIDE INFORMATION ABOUT THE SEVERITY OF THE DISEASE AND THE DURATION OF HOSPITAL STAY. Peripheral blood smear and COVID-19 severity.
3727PDF: 1292HTML: 530 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3300PDF: 1698HTML: 403 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
4113PDF: 831HTML: 1901 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2330PDF: 1680HTML: 715 -
GROUP-BASED TRAJECTORY MODELING OF PLATELET IN PATIENTS WITH APLASTIC ANEMIA: A STUDY BASED ON THE MIMIC DATABASE
1142PDF: 1084Suppl. Files: 678HTML: 203 -
COMPREHENSIVE REVIEW OF GENETIC AND EPIGENETICS REGULATION OF FETAL HEMOGLOBIN IN β-HEMOGLOBINOPATHIES: FROM MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS HbF Genetics in Anemia
1001PDF: 708HTML: 147 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7958PDF: 2525HTML: 2163Table 1.: 277Table 2.: 288Table 3.: 267Table 4.: 263 -
The significance of purity: Leukaemias involving the erythroid lineage Erythroid lineage leukemia
920PDF: 464HTML: 379 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2668PDF: 1801HTML: 723 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2827PDF: 834HTML: 2336 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1281PDF: 883HTML: 3421 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1568PDF: 1411HTML: 123 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1744PDF: 1144HTML: 501 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2235PDF: 1390HTML: 3519 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1433PDF: 1123HTML: 456 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1244PDF: 654Suppl. Files: 153HTML: 545 -
EVALUATION OF USING EMPIRIC GLYCOPEPTIDES IN ACCORDANCE WITH THE IDSA GUIDELINE IN HEMATOLOGIC MALIGNANCY PATIENTS WITH FEBRILE NEUTROPENIA Empiric glycopeptide use in neutropenic fever
1702PDF: 1191HTML: 277







